In 2011, NIA-AA proposed the concept of AD-derived MCI based on etiological classification, indicating that patients at this stage of MCI would eventually develop to the end stage of AD, and suggested, for the first time, Aβ, Tau protein, and biomarkers indicative of neuronal damage as diagnostic criteria for AD-derived MCI [20]. Here, MAPT is linked to Alzheimer disease.